Details

Autor(en) / Beteiligte

• VISCA, Paolo
• SEBASTIANI, Valeria
• ALO, Piero Luigi
• BOTTI, Claudio
• DIODORO, Maria Grazia
• LASAGNI, Roberto Pasquali
• ROMAGNOLI, Francesca
• BRENNA, Alessia
• CAPEZZONE DE JOANNON, Barbara
• PERRONE DONNORSO, Raffaele
• LOMBARDI, Giuseppe

Titel

Fatty Acid Synthase (FAS) is a Marker of Increased Risk of Recurrence in Lung Carcinoma

Ist Teil von

• Anticancer research, 2004-11, Vol.24 (6), p.4169-4173

Ort / Verlag

Attiki: International Institute of Anticancer Research

Erscheinungsjahr

2004

Quelle

MEDLINE

Beschreibungen/Notizen

• Background: We explored the expression of Fatty Acid Synthase (FAS) in lung carcinomas and its association with clinico-pathological features and prognosis. FAS is a recently discovered molecule involved in the energy supply of normal cells. FAS is also overexpressed in neoplastic tissues because of their increased necessity for energy. Patients and Methods: One hundred and six patients with non-small cell lung carcinoma were followed-up for an average period of 5 years. FAS expression was detected immunohistochemically. Results: FAS staining was observed in 61 out of 106 cases (57.54%). Statistical analysis revealed that FAS had an overall low prognostic value (p=0.14), while FAS-negative expression in stage I patients showed a trend for better survival (p=0.10). PTNM stage (p<0.0001) was the only significant prognostic marker for overall survival. Conclusion: FAS is a reliable marker of low-stage clinically aggressive lung carcinomas. The determination of FAS expression in lung carcinomas may stratify patients and determine therapeutic approaches for their care.